News

Viracor-IBT Laboratories, Inc. announced today it has signed a definitive agreement to purchase all assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation.

Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of CylexTM, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. 

New Alpha-Gal IgE assay is the first to specifically detect antibodies associated with a delayed-onset allergic reaction to beef, pork, and lamb, the development of which has been linked to tick bites.

New testing service is the first to detect and measure deadly Invasive Pulmonary Aspergillosis

Scientists from Viracor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year’s American College of Allergy, Asthma and Immunology’s Annual Scientific Meeting in Miami, Florida.

New suite of tests identifies 2009 Influenza A H1N1 ("swine flu"), additional influenza subtypes and other common respiratory viruses, assisting physicians in improving patient care and ensuring appropriate antiviral use.

Combined company draws on latest scientific research to provide the most accurate, reliable and comprehensive immunology and infectious disease tests available.

New test will assist in the earlier diagnosis of Progressive Multifocal Leukoencephalopathy, a serious brain infection exclusively caused by JCV.